An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Tali ShafatDaniel GrupelTzvika PorgesRan AbuhasiraAna BelkinOfir DeriYonatan OsterShadi ZahranEhud HorwitzNetanel A HorowitzHazim KhatibMarjorie Vieira BatistaAnita Cassoli CortezTal Brosh-NissimovYafit SegmanLinor IshayRegev CohenAlaa AtamnaAmy SpalloneRoy F ChemalyJuan Carlos Ramos-RamosMichal ChowersEvgeny RogozinNoga Carmi OrenŞiran KeskeOrit Wolfovitz BarchadLior Neshernull nullPublished in: Cancer medicine (2024)
Despite younger age and a more indolent HM diagnosis, patients receiving obinutuzumab had more severe COVID-19 outcomes than those receiving rituximab. Our findings underscore the need to evaluate the risk-benefit balance when considering obinutuzumab therapy for HM patients during respiratory viral outbreaks.
Keyphrases
- chronic lymphocytic leukemia
- sars cov
- coronavirus disease
- newly diagnosed
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- hodgkin lymphoma
- chronic kidney disease
- prognostic factors
- type diabetes
- respiratory syndrome coronavirus
- early onset
- patient reported outcomes
- metabolic syndrome
- insulin resistance
- respiratory tract